Skip to main content
Fig. 2 | Genome Medicine

Fig. 2

From: Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

Fig. 2

Correlation between JAK2 expression and sensitivity to a selective JAK2 inhibitor fedratinib in NSCLC cell lines. Gene expression data are RMA normalized (log2-based) values derived from microarray gene expression profiling (see “Methods”). a IC50 of fedratinib and JAK2 expression level in 103 NSCLC cell lines. b JAK2 expression in fedratinib sensitive vs. resistant cell lines

Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us